Former FDA No. 2 Amy Abernethy rejoins Robert Califf at Google's Verily, hopping aboard as clinical R&D head

Zachary Brennan

Senior Editor

Google’s life sciences company Verily on Thursday tapped former principal deputy FDA commissioner Amy Abernethy as president of its clinical research business.

The move means …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Former FDA No. 2 Amy Abernethy rejoins Robert Califf at Google's Verily, hopping aboard as clinical R&D head

Zachary Brennan

Senior Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

For­mer FDA No. 2 Amy Aber­nethy re­joins Robert Califf at Google's Ver­i­ly, hop­ping aboard as clin­i­cal R&D head

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Former FDA No. 2 Amy Abernethy rejoins Robert Califf at Google's Verily, hopping aboard as clinical R&D head

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify